Onco-Summaries: Daily Oncology Updates at a Glance

29/09/2025

In an ~$8B deal, Genmab will acquire Merus in an all-cash transaction (Ref)

Genmab and Merus announced a transaction agreement pursuant to which Genmab will acquire all the shares of Merus for $97.00 per share in an all-cash transaction representing a transaction value of ~$8.0 billion.

• The transaction has been unanimously approved by the Boards of Directors of both companies

  
  

• A wholly owned subsidiary of Genmab will commence a tender offer for 100% of Merus’ common shares, which is anticipated to close by Q1'26

AstraZeneca & Daiichi's ENHERTU elicited significant IDFS benefit in early Breast Cancer following neoadjuvant therapy (Ref)

Per topline results from a planned interim analysis of the Phase 3 DESTINY-Breast05 trial, AstraZeneca and Daiichi's trastuzumab deruxtecan (ENHERTU; HER2 ADC) demonstrated a statistically significant and clinically meaningful improvement in IDFS vs trastuzumab emtansine in patients with HER2 +ve early breast cancer with residual invasive disease in the breast or axillary lymph nodes after neoadjuvant treatment and high risk of disease recurrence.

• Overall survival was not mature at the time of this planned interim analysis and will be assessed at a subsequent analysis

  
  

• Detailed results from the trial will be presented at ESMO 2025 Congress (abstract #LBA1 - Presidential Symposium I)

GI Innovation's GI-102 received the FDA fast track designation for Melanoma (Ref)

The US FDA granted the fast track designation to GI Innovation's GI-102 (CD80-IL2v3 immunocytokine) for the treatment of advanced or metastatic Melanoma.

• GI-102, a subcutaneous injection, showed encouraging results in a Phase 1 trial of advanced Melanoma patients who had previously been treated with other immunotherapies.